Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

Eli Lilly is expanding the supply of its weight-loss drug and selling it for half the price of other drugs in the highly lucrative market. Eli Lilly announced on Tuesday that it is now offering ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Eli Lilly is announcing a new way to get its popular Zepbound drug. People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one of ...

Shares of Eli Lilly & Co. LLY slipped 1.88% to $906.18 Tuesday, on what proved to be an all-around mixed trading session for ...

Eli Lilly is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed cheaper, off-brand ...

Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication. By Dani Blum With high demand for drugs ...

Eli Lilly & Co. LLY said Tuesday that patients can now access 2.5- and 5-milligram single-dose vials of its weight-loss treatment Zepbound with an on-label prescription at a discount of at least ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs. The more affordable ...

Eli Lilly is launching singe-use vials of its popular weight-loss drug Zepbound, which will be half the price of previous versions of the drug. The traditional injector pens are more difficult to ...

Sept 9 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately, months after ...

She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market.